+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Phase 2
Age: 18Years - 80Years
All Genders
ID07282912

Phase 2 Trial Comparing Standard Therapy With and Without Sequential Cytoreductive Procedures for Metastatic Foregut Adenocarcinoma Patients With Undetectable ctDNA

Led by Yale University · Updated on 2026-09-08

54

Participants Needed

1

Research Sites

N/A

Total Duration

AI-Summary

What This Trial Is About

Researchers are evaluating a treatment approach for patients with metastatic foregut adenocarcinoma, including cancers of the esophagus, stomach, pancreas, bile ducts, liver, duodenum, ampulla, and gallbladder. This phase 2 randomized trial compares standard systemic therapy alone versus standard therapy combined with sequential cytoreductive interventions in patients who have undetectable circulating tumor DNA ctDNA after receiving induction chemotherapy for three months. The study aims to determine if adding local interventions improves progression-free survival. Participants are randomly assigned to one of two groups after confirming undetectable ctDNA levels one group receives sequential cytoreductive procedures such as surgery, radiation, or ablation over a three-month period, while the other group continues standard systemic therapy alone until disease progression. The sequential interventions are completed within three months post-randomization, and ctDNA levels are monitored during treatment. The study includes diagnostic testing with a personalized blood test to detect ctDNA and assess molecular residual disease. During the study, participants undergo regular assessments including evaluations of progression-free survival up to 12 months after randomization, overall survival at 12 months, and quality of life measures using questionnaires at scheduled weeks and follow-ups. Organ function tests and performance status are monitored, along with financial impact assessments. Safety monitoring and follow-up occur throughout the trial. The study lasts from enrollment through at least 12 months post-randomization, with ongoing collection of clinical and laboratory data.

CONDITIONS

Brief Title

Trial Comparing Standard of Care Therapy With and Without Sequential Cytoreductive Intervention for Patients With Metastatic Foregut Adenocarcinoma and Undetectable Circulating Tumor-Deoxyribose Nucleic Acid (ctDNA) Levels

Research Team

W

Wumi Jemiseye, MPH

N

Nelson Molina

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here